DEMO S.A. Pharmaceutical Industry is an industrial and commercial organization established in 1965 and active in the production and sales of pharmaceutical products.

During the past years, DEMO S.A. has achieved a significant growth in all its business segments. This growth has enabled us to achieve results that are a testament to the quality and dedication of our employees.

  • No1 Producer of pharmaceutical products in Greece
  • No1 in Sales Growth among Greek pharmaceutical companies
  • Within the Top 100 Greek industries
  • No1 company in private funds invested in Greece
  • No1 in new jobs creation in Greece
  • Within the Top 200 Companies in new jobs creation in the European Union
  • Official Supplier of the United Nations
  • Official Supplier of UNICEF

Official Supplier of the United Nations

Within the Top 100 Greek industries

Within the Top 200 Companies in new jobs creation in the European Union

Official Supplier of UNICEF

DEMO S.A. Pharmaceutical Industry is an industrial and commercial organization established in 1965 and active in the production and sales of pharmaceutical products.

We are one of the major pharmaceutical manufacturers in Greece with a very strong presence in the hospital market, ranking first among all the Greek pharmaceutical companies in terms of units sold.

Our product portfolio includes many injectable generic pharmaceutical formulations from several therapeutic categories including: Injectable products of all forms such us Liquid injectables in glass ampoules, vials & bottles, sterile powders and freeze – dried formulations, Lyophilised products, Emulsions, Penems, Penicillins, Cephalosporins).

DEMO S.A. is currently active across 96 countries (as of 31/05/2016), including countries in Europe, Asia, Africa, Latin America, Oceania & the Middle East.

Hospital Market

Anti-infectives

    • Non-beta lactams
    • Cephalosporins
    • Carbapenems
    • Penicillins

Standard solutions
Anesthesia/analgesia
Oncology
Critical care
Parenteral nutrition
Gastric ulcers & gord
Hematology
Respiratory
Central nervοus system (cns)
Medical Devices/ Infusion Pumps

Renal Care

DEMO S.A. started producing its first dialysisproducts in 1996 via a complete range of haemodialysis solutions.

In 1997 our company started distributing the products of a major manufacturer of medical devices for haemodialysis. We concluded an agreement to exclusively distribute their products in Greece, including, but not limited to, haemodialysismachines, haemodialysis filters, fistula needles,catheters, haemostatic pressure bandages & blood lines.

During 2005, our company completed the registration and started manufacturing threehaemodiafiltration solutions. The above activities have placed DEMO S.A. as one of the biggest players in the area of renal services in Greece.

Private Market

RX Products

    • GPs
    • Cardiology
    • Ongology
    • Respiratory
    • Gastroenterology
    • Urology

Medical Devices

    • Solutions for contact lenses
    • Solutions for Eye care
    • Cleaning nozzles for nose and ears

Food Supplements

    • For the Urinary System
    • Liver Health

No1 Producer of pharmaceutical products in Greece

No1 company in private funds invested in Greece

No1 in new jobs creation in Greece

No1 in Sales Growth among Greek pharmaceutical companies

Our company’s Sales and Marketing Departments employ well trained and highly specialized staff. We have a daily presence in all hospital institutions of the country, both public (hospitals) and private (hospitals and clinics).

Our Hematology Department (H.B.U.) promotes pharmaceutical products unique in their category, for example for the treatment of rare hemoglobinopathies, such as thalassemia and sickle cell disease:

  • Ferriprox (deferiprone)
  • Siklos (hydroxycarbamide)

Our company started producing its first renal products in 1996 via a complete range of hemodialysis solutions.

In parallel, it supplies the Greek market with dialysers, catheters, blood lines and dialysis machines.

Binocrit (epoetin-alfa) and Zarzio (filgrastim) are included in Oncology portfolio of our company. Both products are biosimilars and are part of our collaboration with Sandoz, a division of the Novartis Group.

The Oncology portfolio also includes Zoxalon (zoledronic acid), the chemotherapy (Cytototoxic) drugs DEMOZAR (gemcitabine) and  Irinocan (irinotecan) and the biological agent Ιmatinib DEMO.’’

Our company currently provides hospital institutions  with unique and irreplaceable products, such as Adrenaline and other products  assigned directly from EOF.

We also offer a wide range of saline solutions and ampoules.

We provide the Private Market with cardiology, pulmonology, pathology, general medicine, neurology, and urology products.

We offer a complete range of antibiotic products for the efficient treatment of infections in hospitals.


Our vision is to provide quality, as well as reliable and innovative pharmaceutical products worldwide.

Our goal is to be consistently one of the best companies in the pharmaceutical market, maintaining our leadership position in the Greek industry, the positive growth rate and the preference of our customers and partners that is based on their confidence for the products we produce.


DEMO intends to remain on top of the Greek pharmaceutical industry while further establish its position as one of the leading manufacturing companies worldwide.

Having already achieved rapid growth in the global generics pharmaceutical market, we aim to contribute with innovative, quality products and services, improving the lives of patients worldwide and ensuring the steady confidence of our customers. Our modern and fully equipped manufacturing premises, the advanced technologies that we have adopted, our constant product portfolio expansion and our international presence are the means to the end.

Therefore, we have invested heavily in the creation and sourcing of our state-of-the-art Research & Development laboratory. DEMO’s R&D lab spans more than, 1.500 m2 is equipped with the latest instruments and is staffed with the top graduates of the University of Athens. Under the supervision of highly qualified researchers – most of who own PhD degrees from the most acclaimed universities in Europe – our R&D lab represents the company’s launching pad for the future!